CA
ASBP

Crossingbridge Advisors’s Aspire Biopharma ASBP Stock Holding History

Crossingbridge Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.42K Buy
812
+792
+3,960% +$42.2K ﹤0.01% 152
2025
Q4 		$3.21K Hold
20
– – ﹤0.01% 102
2025
Q3 		$7.42K Buy
+20
New +$10K ﹤0.01% 75
2024
Q3 		– Sell
-69
Closed – – 68
2024
Q2 		$0 Buy
+69
New +$940K ﹤0.01% 61

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return

Crossingbridge Advisors's ASBP Position: Q1 2026 in Review

Crossingbridge Advisors increased its Aspire Biopharma (ASBP) stake by 3,960% in Q1 2026, buying an estimated $42.2K and bringing the position to 812 shares worth $7.42K. The position accounts for ﹤0.01% of the portfolio, ranked #152.

Crossingbridge Advisors first reported a position in ASBP in Q2 2024 and has held it in 4 quarters since. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Crossingbridge Advisors held 812 shares of Aspire Biopharma worth $7.42K as of Q1 2026.
  • Crossingbridge Advisors bought 792 Aspire Biopharma shares in Q1 2026, an estimated $42.2K.
  • Aspire Biopharma made up ﹤0.01% of Crossingbridge Advisors's portfolio in Q1 2026, its #152 holding.
  • Crossingbridge Advisors first reported a position in Aspire Biopharma in Q2 2024 and has held it in 4 quarters since.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Crossingbridge Advisors's 13F filing for Q1 2026, filed 14 May 2026.